Viral Hepatitis

You have full text access to this OnlineOpen article

Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1–infected patients†‡

  1. Thomas Berg1,§,*,
  2. Viola Weich1,
  3. Gerlinde Teuber2,
  4. Hartwig Klinker3,
  5. Bernd Möller4,
  6. Jens Rasenack5,
  7. Holger Hinrichsen6,
  8. Tilman Gerlach7,
  9. Ulrich Spengler8,
  10. Peter Buggisch9,
  11. Heike Balk10,
  12. Myrga Zankel10,
  13. Konrad Neumann11,
  14. Christoph Sarrazin2,
  15. Stefan Zeuzem2

Article first published online: 6 APR 2009

DOI: 10.1002/hep.22991

Issue

Hepatology

Hepatology

Volume 50, Issue 2, pages 369–377, August 2009

Additional Information

How to Cite

Berg, T., Weich, V., Teuber, G., Klinker, H., Möller, B., Rasenack, J., Hinrichsen, H., Gerlach, T., Spengler, U., Buggisch, P., Balk, H., Zankel, M., Neumann, K., Sarrazin, C. and Zeuzem, S. (2009), Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1–infected patients. Hepatology, 50: 369–377. doi: 10.1002/hep.22991

Author Information

  1. 1

    Universitätsklinikum Charité, Campus Virchow-Klinikum, Universitätsmedizin Berlin, Berlin, Germany

  2. 2

    Medizinische Klinik 1, Klinikum der Johann Wolfgang Goethe Universität Frankfurt a.M., Frankfurt, Germany

  3. 3

    Medizinische Klinik und Poliklinik II der Universität Würzburg, Würzburg, Germany

  4. 4

    Hepatologische Schwerpunktpraxis Charlottenburger Str., Berlin, Germany

  5. 5

    Medizinische Universitätsklinik Freiburg, Freiburg, Germany

  6. 6

    Klinikum der Christian-Albrechts-Universität, Kiel, Germany

  7. 7

    Klinikum Großhadern, Ludwig-Maximilians-Universität, München, Germany

  8. 8

    Medizinische Universitätsklinik II, Bonn, Germany

  9. 9

    Medizinische Universitätsklinik Eppendorf, Hamburg, Germany

  10. 10

    Essex Pharma GmbH, München, Germany

  11. 11

    Charité, Institut für Biometrie und Klinische Epidemiologie, Berlin, Germany

  1. §

    fax: (49)-30-450-553903.

*Medizinische Klinik m. S. Hepatologie und Gastroenterologie, Charité, Campus Virchow-Klinikum, Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany

  1. †

    Presented in part at the Annual Meetings of the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases in 2006.

  2. ‡

    Potential conflicts of interest: Dr. Berg advises, is on the speakers' bureau of, and received grants from Roche and Schering-Plough. Dr. Klinker is a consultant for and lectures for Bristol-Myers Squibb, and GlaxoSmithKline. He also lectures for Boehringer Ingelheim, Roche, Gilead, and Tibotec. He lectures for and received grants from Essex. He is a consultant for Merck Sharp & Dohme and received grants from Abbott. Dr. Buggisch is on the speakers' bureau of Roche. Dr. Sarrazin is on the speakers' bureau of and received grants from Essex. Dr. Zeuzem is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche and Schering-Plough.

Publication History

  1. Issue published online: 29 JUL 2009
  2. Article first published online: 6 APR 2009
  3. Accepted manuscript online: 6 APR 2009 12:00AM EST
  4. Manuscript Accepted: 15 MAR 2009
  5. Manuscript Received: 25 OCT 2008

Funded by

  • Essex Pharma (Munich, Germany), a subsidiary of Schering-Plough (Kenilworth, NJ)
  • Bayer Diagnostics
  • German Competence Network for Viral Hepatitis (Kompetenznetz Hepatitis, Hep-Net), funded by the German Ministry of Education and Research. Grant Number: 01 KI 0102
  • VIRGIL European Network of Excellence Combating Viral Resistance to Treatments

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (394K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Janett Fischer, Stephan Böhm, Markus Scholz, Tobias Müller, Heiko Witt, Jacob George, Christoph Sarrazin, Simone Susser, Eckart Schott, Vijayaprakash Suppiah, David R. Booth, Graeme J. Stewart, Florian van Bömmel, Annika Brodzinski, Balazs Fülöp, Pascal Migaud, Thomas Berg, Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection, Hepatology, 2012, 55, 6
    Direct Link:
  2. 2
    Chung-Feng Huang, Jee-Fu Huang, Jeng-Fu Yang, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Liang-Yen Wang, Suh-Hang Hank Juo, Ku-Chung Chen, Wan-Long Chuang, Hsing-Tao Kuo, Chia-Yen Dai, Ming-Lung Yu, Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin, Journal of Hepatology, 2012, 56, 1, 34

    CrossRef

  3. 3
    A. Craxi, S. Koutsounas, P. Ogurtsov, L. Chemello, M. Maticic, J. Torras, M. Diago, M. T. Tartaglione, T. Witthoeft, X. Yu, R. Faruqi, E. Chaudhri, L. D. Pedicone, E. Zuckerman, Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response, Journal of Viral Hepatitis, 2012, 19, 2
    Direct Link:
  4. 4
    K. Rajender Reddy, Frederick Lin, Fabien Zoulim, Response-guided and -unguided treatment of chronic hepatitis C, Liver International, 2012, 32,
    Direct Link:
  5. 5
    J. Wiegand, K. Neumann, S. Bohm, V. Weich, G. Teuber, H. Klinker, B. Moller, J. Rasenack, H. Hinrichsen, T. Gerlach, U. Spengler, P. Buggisch, C. Sarrazin, T. Berg, Importance of Minimal Residual Viremia for Relapse Prediction in Patients With Chronic Hepatitis C Genotype 1 Infection, Clinical Infectious Diseases, 2011, 53, 11, 1111

    CrossRef

  6. 6
    Christoph Sarrazin, Susanne Schwendy, Bernd Möller, Nektarios Dikopoulos, Peter Buggisch, Jens Encke, Gerlinde Teuber, Tobias Goeser, Robert Thimme, Hartwig Klinker, Wulf O. Boecher, Ewert Schulte–Frohlinde, Renate Prinzing, Eva Herrmann, Stefan Zeuzem, Thomas Berg, Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24–72 Weeks, Gastroenterology, 2011, 141, 5, 1656

    CrossRef

  7. 7
    Hidenori Toyoda, Takashi Kumada, Seiki Kiriyama, Makoto Tanikawa, Yasuhiro Hisanaga, Akira Kanamori, Toshifumi Tada, Takanori Hosokawa, Takahiro Arakawa, Masashi Fujimori, Outcome in partial early virologic responders to combination therapy with peginterferon and ribavirin in patients infected with hepatitis C virus genotype 1b, Journal of Medical Virology, 2011, 83, 1
    Direct Link:
  8. 8
    Vincent Di Martino, Carine Richou, Jean-Paul Cervoni, Jose M. Sanchez-Tapias, Donald M. Jensen, Alessandra Mangia, Maria Buti, Frances Sheppard, Peter Ferenci, Thierry Thévenot, Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized, controlled trials and implications for the future, Hepatology, 2011, 54, 3
    Direct Link:
  9. 9
    Ming-Lung Yu, Chung-Feng Huang, Jee-Fu Huang, Ning-Chia Chang, Jeng-Fu Yang, Zu-Yau Lin, Shinn-Cherng Chen, Ming-Yuh Hsieh, Liang-Yen Wang, Wen-Yu Chang, Yi-Ning Li, Mei-Shin Wu, Chia-Yen Dai, Suh-Hang Hank Juo, Wan-Long Chuang, Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients, Hepatology, 2011, 53, 1
    Direct Link:
  10. 10
    Zvi Ackerman, Orit Pappo, Iddo Z. Ben-Dov, The prognostic value of changes in serum ferritin levels during therapy for hepatitis C virus infection, Journal of Medical Virology, 2011, 83, 7
    Direct Link:
  11. 11
    Christoph Sarrazin, Mitchell L. Shiffman, Stephanos J. Hadziyannis, Amy Lin, Giuseppe Colucci, Hiroshi Ishida, Stefan Zeuzem, Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy, Journal of Hepatology, 2010, 52, 6, 832

    CrossRef

  12. 12
    R. Todd Frederick, Hepatitis C Assays: The Pitfalls of Polymerase Chain Reaction and Genotyping, Current Hepatitis Reports, 2010, 9, 1, 9

    CrossRef

  13. 13
    Christian Markus Lange, Kirsten Roomp, Anette Dragan, Jacob Nattermann, Monika Michalk, Ulrich Spengler, Viola Weich, Thomas Lengauer, Stefan Zeuzem, Thomas Berg, Christoph Sarrazin, HLA class I allele associations with HCV genetic variants in patients with chronic HCV genotypes 1a or 1b infection, Journal of Hepatology, 2010, 53, 6, 1022

    CrossRef

  14. 14
    Alessandra Mangia, Franco Bandiera, Giuseppe Montalto, Leonardo Mottola, Valeria Piazzolla, Nicola Minerva, Adriano Pellicelli, Giovanni L. Ricci, Marina Cela, Vito Carretta, Gaetano Scotto, Donato Bacca, Brigida Annicchiarico, Mario Romano, Maurizio Russello, Giorgio Barbarini, Ernesto Agostinacchio, Angelo Andriulli, Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3, Journal of Hepatology, 2010, 53, 6, 1000

    CrossRef

  15. 15
    Stefan Zeuzem, Fred Poordad, Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response, Current Medical Research and Opinion, 2010, 26, 7, 1733

    CrossRef

  16. 16
    Hidenori Toyoda, Takashi Kumada, Seiki Kiriyama, Makoto Tanikawa, Yasuhiro Hisanaga, Akira Kanamori, Toshifumi Tada, Makiko Takagi, Takeshi Hiramatsu, Takanori Hosokawa, Takahiro Arakawa, Masashi Fujimori, Transient reappearance of serum hepatitis C virus RNA observed by real-time PCR during antiviral therapy with peginterferon and ribavirin in patients with HCV genotype 1b, Journal of Clinical Virology, 2010, 47, 3, 258

    CrossRef

  17. 17
    Lior H Katz, Hadar Goldvaser, Anat Gafter-Gvili, Ran Tur-Kaspa, Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks for patients with chronic hepatitis C virus genotype 1 infection having shown slow antiviral response, The Cochrane Library,
    Direct Link:
  18. 18
    Jama M. Darling, Stanley M. Lemon, Michael W. Fried, Hepatitis C,
    Direct Link:
  19. 19
    Geoffrey Dusheiko, Hepatitis C,
    Direct Link:
  20. 20
    Johannes Wiegand, Thomas Berg, Individually Tailored Treatment Strategies in Treatment-naïve Chronic Hepatitis C Genotype 1 Patients,
    Direct Link:
View Full Article with Supporting Information (HTML) Get PDF (394K)